Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Inclusion Criteria

• •A histologically or cytologically confirmed diagnosis of non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
• •Must have measurable disease by CT or MRI scan
• •Must have relapsed radiologically with a randomization date within ≥6 and \< 24 months of completion of first-line platinum chemotherapy
• •Have been treated with debulking surgery and first-line platinum and taxane based chemotherapy.
• •Prior bevacizumbab maintenance is allowed. The last dose of bevacizumab must have been at least 30 days before study Day 1. No cytotoxic maintenance therapy (e.g. taxane) or cancer vaccine therapy is allowed.
• •Must be a candidate for carboplatin and taxane therapy
• •Neurologic function: neuropathy (sensory and motor) ≤CTCAE Grade 1